AGIOS PHARMACEUTICALS, INC. Earnings Per Share (Diluted)
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Earnings Per Share (Diluted) of -$1.69 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$1.69.
- AGIOS PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$1.69.
- AGIOS PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2025-12-31 was -$1.86.
- AGIOS PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$1.78, a 110.97% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2025 was -$7.12, a 161.17% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2024 was $11.64.
- AGIOS PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2023 was -$6.33.
- AGIOS PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2022 was -$4.23, a 115.93% decline from fiscal 2021.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.69 10-Q · filed 2026-07-30 | -$3.38 10-Q · filed 2026-07-30 | -$5.23 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$7.01 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2026-03-31 | -$1.69 10-Q · filed 2026-04-29 | -$3.54 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$5.32 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$7.25 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-12-31 | -$1.86 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$3.63 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$5.57 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$7.12 10-K · filed 2026-02-12 |
| 2025-09-30 | -$1.78 10-Q · filed 2025-10-30 | -$3.71 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$5.27 10-Q · filed 2025-10-30 | -$6.90 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-06-30 | -$1.93 10-Q · filed 2026-07-30 | -$3.49 10-Q · filed 2026-07-30 | -$5.12 derived: net income ÷ weighted average shares · filed 2026-07-30 | $11.18 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-03-31 | -$1.55 10-Q · filed 2026-04-29 | -$3.19 derived: net income ÷ weighted average shares · filed 2026-07-30 | $13.09 derived: net income ÷ weighted average shares · filed 2026-07-30 | $11.51 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2024-12-31 | -$1.64 derived: net income ÷ weighted average shares · filed 2026-04-24 | $14.53 derived: net income ÷ weighted average shares · filed 2026-04-24 | $13.02 derived: net income ÷ weighted average shares · filed 2026-04-24 | $11.64 10-K · filed 2026-02-12 |
| 2024-09-30 | $16.22 10-Q · filed 2025-10-30 | $14.78 derived: net income ÷ weighted average shares · filed 2025-10-30 | $13.38 10-Q · filed 2025-10-30 | $11.86 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2024-06-30 | -$1.69 10-Q · filed 2025-07-31 | -$3.14 10-Q · filed 2025-07-31 | -$4.85 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$6.49 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2024-03-31 | -$1.45 10-Q · filed 2025-05-01 | -$3.16 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$4.80 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$6.30 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2023-12-31 | -$1.71 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$3.35 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$4.86 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$6.33 10-K · filed 2026-02-12 |
| 2023-09-30 | -$1.64 10-Q · filed 2024-10-31 | -$3.14 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$4.61 10-Q · filed 2024-10-31 | -$3.97 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2023-06-30 | -$1.51 10-Q · filed 2024-08-01 | -$2.97 10-Q · filed 2024-08-01 | -$2.32 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$3.81 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2023-03-31 | -$1.47 10-Q · filed 2024-05-02 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$2.30 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$3.97 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2022-12-31 | $0.66 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$2.50 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$4.23 10-K · filed 2025-02-13 |
| 2022-09-30 | -$1.49 10-Q · filed 2023-11-02 | -$3.17 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$4.90 10-Q · filed 2023-11-02 | -$6.64 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2022-06-30 | -$1.68 10-Q · filed 2023-08-03 | -$3.41 10-Q · filed 2023-08-03 | -$5.15 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$6.70 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2022-03-31 | -$1.74 10-Q · filed 2023-05-04 | -$3.48 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$5.03 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$6.42 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2021-12-31 | -$1.74 10-K · filed 2022-02-24 | -$3.29 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$4.69 derived: net income ÷ weighted average shares · filed 2026-04-24 | $26.55 10-K · filed 2024-02-15 |
| 2021-09-30 | -$1.56 10-Q · filed 2022-11-03 | -$2.96 derived: net income ÷ weighted average shares · filed 2022-11-03 | $27.19 10-Q · filed 2022-11-03 | $24.94 derived: net income ÷ weighted average shares · filed 2023-02-23 |
| 2021-06-30 | -$1.41 10-Q · filed 2022-08-04 | $27.39 10-Q · filed 2022-08-04 | $25.37 derived: net income ÷ weighted average shares · filed 2023-02-23 | $23.66 derived: net income ÷ weighted average shares · filed 2023-02-23 |
| 2021-03-31 | $26.95 10-Q · filed 2022-05-05 | $25.60 derived: net income ÷ weighted average shares · filed 2023-02-23 | $24.20 derived: net income ÷ weighted average shares · filed 2023-02-23 | $22.93 derived: net income ÷ weighted average shares · filed 2023-02-23 |
| 2020-12-31 | -$1.41 10-K · filed 2022-02-24 | -$2.84 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$4.15 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$4.74 10-K · filed 2023-02-23 |
| 2020-09-30 | -$1.43 10-K · filed 2022-02-24 | -$2.74 derived: net income ÷ weighted average shares · filed 2021-11-03 | -$3.33 10-Q · filed 2021-11-03 | |
| 2020-06-30 | -$1.31 10-K · filed 2022-02-24 | -$1.90 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | -$0.59 10-K · filed 2022-02-24 | |||
| 2019-12-31 | -$6.86 10-K · filed 2022-02-24 | |||
| 2015-09-30 | -$1.07 10-Q · filed 2015-11-06 | -$2.06 10-Q · filed 2015-11-06 | ||
| 2014-12-31 | -$0.76 10-K · filed 2016-02-26 | |||
| 2014-09-30 | $0.10 10-K · filed 2016-02-26 | -$0.81 10-Q · filed 2015-11-06 | ||
| 2014-06-30 | -$0.54 10-K · filed 2016-02-26 | |||
| 2014-03-31 | -$0.39 10-K · filed 2016-02-26 | |||
| 2013-09-30 | -$0.52 10-Q · filed 2014-11-07 | -$3.08 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |